Evidence map›Paper›PMID 41775339›Full record

Trial reportContact dermatitis2026

Effect of Delgocitinib Cream on Health-Related Quality of Life in Patients With Moderate to Severe Chronic Hand Eczema.

Andrea Bauer, Lyn Guenther, Richard Woolf, Eydna Didriksen Apol, Douglas Maslin, Nanna Nyholm, Henrik Thoning, Marie Louise Schuttelaar

2 registry-linked trialsAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Contact dermatitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04871711 phase3completednot on this map

A Phase 3 Clinical Trial to Confirm Efficacy and Evaluate Safety of Twice-daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adult Subjects With Moderate to Severe Chronic Hand Eczema (DELTA 1)

TypeinterventionalSponsorLEO PharmaRan2021 to 2022Enrolled487ConditionsChronic Hand EczemaArmsDelgocitinib cream, Cream vehicle
NCT04872101 phase3completednot on this map

A Phase 3 Clinical Trial to Confirm Efficacy and Evaluate Safety of Twice-daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adult Subjects With Moderate to Severe Chronic Hand Eczema (DELTA 2)

TypeinterventionalSponsorLEO PharmaRan2021 to 2023Enrolled473ConditionsChronic Hand EczemaArmsDelgocitinib cream, Cream vehicle
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andrea BauerDepartment of Dermatology, University Allergy Centre, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany.
Lyn GuentherDivision of Dermatology, Department of Medicine, Western University, London, Ontario, Canada.
Richard WoolfSt John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Eydna Didriksen ApolLEO Pharma A/S, Ballerup, Denmark.ORCID https://orcid.org/0009-0006-4441-4784
Douglas MaslinLEO Pharma A/S, Ballerup, Denmark.
Nanna NyholmLEO Pharma A/S, Ballerup, Denmark.
Henrik ThoningLEO Pharma A/S, Ballerup, Denmark.
Marie Louise SchuttelaarDepartment of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID https://orcid.org/0000-0002-0766-4382

Funding

LEO Pharma
6 · The paper itself

Abstract

backgroundChronic Hand Eczema (CHE) is a multifactorial, fluctuating inflammatory disease of the hands and wrists that negatively impacts patients' health-related quality of life (HRQoL).

objectivesTo assess the effects of delgocitinib cream versus cream vehicle on HRQoL.

methodsDELTA 1 and DELTA 2 were phase 3 trials of identical design in which adults with moderate to severe CHE were randomised (2:1) to double-blind treatment with delgocitinib cream 20 mg/g or cream vehicle twice daily for 16 weeks. Data were pooled from both trials and changes in EQ-5D, Dermatology Life Quality Index (DLQI), and Hand Eczema Impact Scale (HEIS), including the HEIS Proximal Daily Activity Limitations (PDAL) and HEIS Embarrassment (Emb) subsets, were compared.

resultsAcross the two trials, 639 patients were randomised to delgocitinib cream and 321 to cream vehicle. Delgocitinib cream resulted in significantly greater improvement in EQ-5D, DLQI, HEIS, HEIS PDAL, and HEIS Emb compared with cream vehicle at week 16 (all p < 0.001). More patients achieved clinically meaningful improvement from baseline in patient-reported outcomes at week 16 (all p < 0.001), and the mean time spent in an improved HRQoL state increased with delgocitinib cream.

conclusionsDelgocitinib cream resulted in clinically significant improvement in HRQoL compared with cream vehicle. CLINICAL TRIAL ID: DELTA 1 (NCT04871711) and DELTA 2 (NCT04872101).

Indexed as

Dermatologic AgentsEczemaHand DermatosesPyrrolesQuality of LifeAdultAgedChronic DiseaseDouble-Blind MethodFemaleHumansMaleMiddle AgedSeverity of Illness IndexSkin CreamTreatment OutcomedelgocitinibDermatologic AgentsPyrrolescontact dermatitiseczemahand eczema impact scalehealth‐related quality of life

Identifiers

PMID41775339
PMCPMC13238450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.